Celyad OncologyCLYYF 28 PB Ratio is 3.91 as of Jun. 26, 2026, which is 76% above its 10-year median of 2.22. GuruFocus rates CLYYF with a GF Score™ of 28/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,232 Biotechnology companies, Celyad Oncology ranks worse than 68.83% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Celyad Oncology's share price is $0.25. Celyad Oncology's Book Value per Share for the quarter that ended in Dec. 2025 was $0.06. Hence, Celyad Oncology's PB Ratio of today is 3.91.
Good Sign:
Celyad Oncology SA stock PB Ratio (=4.81) is close to 1-year low of 4.81.
The historical rank and industry rank for Celyad Oncology's PB Ratio or its related term are showing as below:
CLYYF'
s PB Ratio Range Over the Past 10 Years
Min: 0.08 Med: 2.22 Max: 56.83
Current: 4.81
During the past 13 years, Celyad Oncology's highest PB Ratio was 56.83. The lowest was 0.08. And the median was 2.22.
CLYYF's PB Ratio is ranked worse than 68.83% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs CLYYF: 4.81
During the past 12 months, Celyad Oncology's average Book Value Per Share Growth Rate was 350.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -34.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -62.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -47.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Celyad Oncology was 205.40% per year. The lowest was -81.60% per year. And the median was -27.00% per year.
Back to Basics: PB Ratio
Celyad Oncology (OTCPK:CLYYF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Celyad Oncology PB Ratio Related Terms
Celyad Oncology PB Ratio Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Celyad Oncology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Celyad Oncology's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Celyad Oncology (CLYYF) has a PB Ratio of 3.91 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Celyad Oncology and its competitors. This is 76% above median its historical median of 2.22. Over the past decade, Celyad Oncology's PB Ratio has ranged from 0.08 to 56.83. According to the industry distribution chart, Celyad Oncology ranks #848 out of 1232 companies in the Biotechnology industry, placing it in the top 68.8%.
Is Celyad Oncology's PB Ratio too high?
Celyad Oncology's current PB Ratio of 3.91 is 76% above median its 10-year median of 2.22. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 56.83. The Biotechnology industry median PB Ratio is 2.80. Celyad Oncology's value of 3.91 is 39.6% above this industry median. Based on the distribution chart, Celyad Oncology ranks #848 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Celyad Oncology has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #848 out of 1232 companies for PB Ratio. This places Celyad Oncology in the lower half of its industry. The industry median PB Ratio is 2.80. Celyad Oncology's value of 3.91 is 39.6% above this benchmark. Historically, Celyad Oncology's own PB Ratio has ranged from 0.08 to 56.83 over the past decade. While the company's 10-year median is 2.22 vs. the industry median of 2.80, Celyad Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celyad Oncology's current PB Ratio of 3.91 is 39.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Celyad Oncology and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celyad Oncology's current PB Ratio is 3.91, which is 76% above median its own 10-year median of 2.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.25 — trading 66.7% above its estimated fair value. The current PB Ratio is 3.91, which is 76% above median its 10-year median of 2.22 and 39.6% above the Biotechnology industry median of 2.80. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current PB Ratio is 3.91 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celyad Oncology (CLYYF) Overvalued in 2026?
Based on GuruFocus' analysis, Celyad Oncology stock appears to be overvalued.
The current stock price of $0.25 is trading 66.7% above its estimated GF Value™ of $0.15.
GuruFocus considers Celyad Oncology to be Significantly Overvalued.
Key valuation signals for CLYYF:
PB Ratio: 3.91 (76% above median its 10-year median of 2.22)
GF Value™: $0.15 vs. price of $0.25 (66.7% above fair value)
Industry Position: 39.6% above the Biotechnology median (#848 of 1232)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score
Get the complete analysis for CLYYF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
